Authors:
P Portincasa, M Vacca, A Moschetta, M Petruzzelli, G Palasciano, KJ van Erpecum, GP van Berge-Henegouwen
Journal name: 
World J Gastroenterol
Citation info: 
11(1):7-16
Abstract: 
Primary sclerosing cholangitis (PSC) is a chronic cholestatic syndrome of unknown origin mostly found in males, and characterized by diffuse inflammation and fibrosis of both intra- and extra-hepatic bile ducts. So far, PSC is considered as an autoimmune hepatobiliary disease. In most cases the progression of PSC towards liver cirrhosis and liver failure is slow but irreversible, and liver transplantation is currently the only definitive treatment. In recent years, PSC has been an area of active research worldwide with great interest in etiology, pathogenesis, diagnosis, and therapeutic options such as hydrophilic ursodeoxycholic acid and immunosuppressive agent tacrolimus. Recent updates on clinical and therapeutic aspects of PSC are discussed in the present review.
DOI: 
http://doi.org/10.3748/wjg.v11.i1.7
E-pub date: 
31 Dec 2004
Users with this publication listed: 
Michele Petruzzelli